CN1886384A - 喹唑酮化合物作为抗癌药剂 - Google Patents

喹唑酮化合物作为抗癌药剂 Download PDF

Info

Publication number
CN1886384A
CN1886384A CNA2004800348103A CN200480034810A CN1886384A CN 1886384 A CN1886384 A CN 1886384A CN A2004800348103 A CNA2004800348103 A CN A2004800348103A CN 200480034810 A CN200480034810 A CN 200480034810A CN 1886384 A CN1886384 A CN 1886384A
Authority
CN
China
Prior art keywords
oxo
chloro
compound
unsubstituted
replacement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800348103A
Other languages
English (en)
Chinese (zh)
Inventor
王为波
L·M·拉格尼顿
R·N·康斯坦丁
M·C·德赛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOVARTIS VACCINES and DIAGNOSTIC Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of CN1886384A publication Critical patent/CN1886384A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2004800348103A 2003-11-25 2004-11-24 喹唑酮化合物作为抗癌药剂 Pending CN1886384A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52505903P 2003-11-25 2003-11-25
US60/525,059 2003-11-25

Publications (1)

Publication Number Publication Date
CN1886384A true CN1886384A (zh) 2006-12-27

Family

ID=34632957

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800348103A Pending CN1886384A (zh) 2003-11-25 2004-11-24 喹唑酮化合物作为抗癌药剂

Country Status (17)

Country Link
US (2) US7939539B2 (https=)
EP (1) EP1689724B1 (https=)
JP (2) JP4778439B2 (https=)
KR (1) KR20060127413A (https=)
CN (1) CN1886384A (https=)
AT (1) ATE538103T1 (https=)
AU (1) AU2004293464A1 (https=)
CA (1) CA2546932A1 (https=)
CY (1) CY1112478T1 (https=)
DK (1) DK1689724T3 (https=)
ES (1) ES2376552T3 (https=)
IL (1) IL175714A0 (https=)
PL (1) PL1689724T3 (https=)
PT (1) PT1689724E (https=)
SG (1) SG148202A1 (https=)
SI (1) SI1689724T1 (https=)
WO (1) WO2005051922A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101250189B (zh) * 2008-03-25 2010-06-16 中山大学 双脂肪氨基取代喹唑酮衍生物及其制备方法与作为抗癌药物的应用
CN101857595A (zh) * 2010-05-21 2010-10-13 中山大学 一种喹唑酮衍生物及其制备方法和作为抗癌药物的用途
CN101899009A (zh) * 2010-07-30 2010-12-01 江苏昊华精细化工有限公司 医药中间体4(h)喹唑酮的制造方法
CN101967127A (zh) * 2010-09-28 2011-02-09 中山大学 一种喹唑啉衍生物及其制备方法和制备抗癌药物中的应用
CN103012291A (zh) * 2012-12-17 2013-04-03 中山大学 一种2-苯基喹唑啉衍生物及其制备方法与在制备抗癌药物中的应用

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7671200B2 (en) * 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
WO2003070701A2 (en) * 2002-02-15 2003-08-28 Cytokinetics, Inc. Syntheses of quinazolinones
US7214800B2 (en) * 2002-05-09 2007-05-08 Cytokinetics, Inc. Compounds, compositions, and methods
EP1513820A4 (en) 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
AU2003256805A1 (en) 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
WO2004034972A2 (en) * 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods
NZ551004A (en) 2004-04-02 2010-07-30 Prana Biotechnology Ltd Neurologically-active compounds
CN101027309B (zh) 2004-08-18 2010-10-27 阿斯利康(瑞典)有限公司 所选择的稠合嘧啶酮的对映体和在治疗和预防癌症中的用途
EP1786265A4 (en) * 2004-08-30 2009-08-19 Smithkline Beecham Corp NEW COMPOSITIONS AND PROCESSING METHODS
US20080064680A1 (en) * 2004-09-14 2008-03-13 Bamdad Cynthia C Methods for Diagnosis and Treatment of Cancer
CA2669917A1 (en) 2006-11-17 2008-05-22 Dawn M. George Aminopyrrolidines as chemokine receptor antagonists
KR100916160B1 (ko) * 2007-02-21 2009-09-08 (주)바이오버드 약제학적 항암 조성물
WO2009102537A1 (en) * 2008-02-14 2009-08-20 Merck & Co., Inc. Inhibitors of checkpoint kinases
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2855483B1 (en) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinone compounds
NZ708864A (en) 2012-12-21 2016-09-30 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
JP6207100B2 (ja) 2012-12-21 2017-10-04 ギリアード カリストガ エルエルシー イソキノリノンまたはキナゾリノンホスファチジルイノシトール３−キナーゼ阻害剤
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
MX2015016344A (es) 2013-05-27 2016-03-01 Novartis Ag Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
CA2912986A1 (en) 2013-05-28 2014-12-04 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
US9714249B2 (en) 2013-05-28 2017-07-25 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
ES2667173T3 (es) 2013-06-14 2018-05-09 Gilead Calistoga Llc Inhibidores de fosfatidilinositol 3-quinasa
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
US9550796B2 (en) 2013-11-21 2017-01-24 Novartis Ag Pyrrolopyrrolone derivatives and their use as BET inhibitors
PL3086814T3 (pl) 2013-12-23 2020-12-28 Bayer Pharma Aktiengesellschaft Koniugaty środka wiążącego (ADC) z inhibitorami KSP
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN107635586B (zh) 2014-12-15 2021-09-24 拜耳医药股份有限公司 Ksp抑制剂与无糖基化抗-tweakr抗体的抗体-药物缀合物(adc)
RU2751512C2 (ru) 2015-06-22 2021-07-14 Байер Фарма Акциенгезельшафт Конъюгаты антитела и лекарственного средства (adc) и конъюгаты антитела и пролекарства (apdc), содержащие ферментативно расщепляемые группы
US11071788B2 (en) 2015-06-23 2021-07-27 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies
WO2016207094A1 (de) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-tweakr-antikörpern
WO2017003723A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017216028A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
JP7066714B2 (ja) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
JP7030811B2 (ja) 2016-12-21 2022-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ）
US11028068B2 (en) 2017-07-25 2021-06-08 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
JP2021527640A (ja) 2018-06-18 2021-10-14 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 酵素的に切断可能なリンカーおよび改善された活性プロファイルを有する、ｃｘｃｒ５に対して向けられるバインダー／活性薬剤複合体
CN111499634B (zh) * 2019-01-31 2023-05-12 贝达药业股份有限公司 一种喹唑啉化合物及其在医药上的应用
WO2021086038A1 (ko) 2019-10-31 2021-05-06 홀로스메딕 주식회사 신규한 화합물 및 이를 포함하는 암 예방 또는 치료용 약학 조성물
KR102682775B1 (ko) 2020-06-26 2024-07-08 홀로스메딕 주식회사 신규한 화합물의 제조방법
WO2022231377A1 (ko) 2021-04-29 2022-11-03 홀로스메딕 주식회사 신규한 화합물 및 이를 포함하는 암 예방 또는 치료용 약학 조성물 및 그의 용도
KR102862736B1 (ko) * 2022-12-07 2025-09-22 부산대학교 산학협력단 신규 2-((트랜스-4-(4-아릴옥시)사이클로헥실)아미노)퀴나졸리논 유도체 및 이의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4329418A1 (de) * 1993-09-01 1995-03-02 Agfa Gevaert Ag Gelbkuppler
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
ATE327224T1 (de) * 1999-10-27 2006-06-15 Cytokinetics Inc Chinazolinone benutzende verfahren und zusammenstellungen
JP2002296741A (ja) * 2001-03-30 2002-10-09 Fuji Photo Film Co Ltd 色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物
US6677110B2 (en) * 2001-03-30 2004-01-13 Fuji Photo Film Co., Ltd. Dye-forming coupler, silver halide photographic light-sensitive material, and azomethine dye compound
JP4267838B2 (ja) * 2001-03-30 2009-05-27 富士フイルム株式会社 色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物
JP2002318442A (ja) * 2001-04-20 2002-10-31 Fuji Photo Film Co Ltd 色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物
JP4267840B2 (ja) * 2001-04-20 2009-05-27 富士フイルム株式会社 色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物
CA2465491A1 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
US7378411B2 (en) * 2001-12-06 2008-05-27 Merck & Co., Inc. Substituted thienopyrimidinones as a mitotic kinesin inhibitor
US7214800B2 (en) 2002-05-09 2007-05-08 Cytokinetics, Inc. Compounds, compositions, and methods
EP1513820A4 (en) 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
WO2004039774A2 (en) 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
US20040048853A1 (en) 2002-08-21 2004-03-11 Gustave Bergnes Compounds, compositions, and methods
WO2004034972A2 (en) 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101250189B (zh) * 2008-03-25 2010-06-16 中山大学 双脂肪氨基取代喹唑酮衍生物及其制备方法与作为抗癌药物的应用
CN101857595A (zh) * 2010-05-21 2010-10-13 中山大学 一种喹唑酮衍生物及其制备方法和作为抗癌药物的用途
CN101857595B (zh) * 2010-05-21 2012-11-21 中山大学 一种喹唑酮衍生物及其制备方法和作为抗癌药物的用途
CN101899009A (zh) * 2010-07-30 2010-12-01 江苏昊华精细化工有限公司 医药中间体4(h)喹唑酮的制造方法
CN101899009B (zh) * 2010-07-30 2012-04-04 江苏昊华精细化工有限公司 医药中间体4(h)喹唑酮的制造方法
CN101967127A (zh) * 2010-09-28 2011-02-09 中山大学 一种喹唑啉衍生物及其制备方法和制备抗癌药物中的应用
CN101967127B (zh) * 2010-09-28 2013-05-29 中山大学 一种喹唑啉衍生物及其制备方法和制备抗癌药物中的应用
CN103012291A (zh) * 2012-12-17 2013-04-03 中山大学 一种2-苯基喹唑啉衍生物及其制备方法与在制备抗癌药物中的应用

Also Published As

Publication number Publication date
PT1689724E (pt) 2012-02-06
JP2011084570A (ja) 2011-04-28
EP1689724A1 (en) 2006-08-16
ATE538103T1 (de) 2012-01-15
IL175714A0 (en) 2006-09-05
DK1689724T3 (da) 2012-02-27
WO2005051922A1 (en) 2005-06-09
US20050209254A1 (en) 2005-09-22
CA2546932A1 (en) 2005-06-09
JP4778439B2 (ja) 2011-09-21
CY1112478T1 (el) 2015-12-09
SI1689724T1 (sl) 2012-04-30
KR20060127413A (ko) 2006-12-12
US7939539B2 (en) 2011-05-10
US20110190293A1 (en) 2011-08-04
ES2376552T3 (es) 2012-03-14
AU2004293464A1 (en) 2005-06-09
EP1689724B1 (en) 2011-12-21
SG148202A1 (en) 2008-12-31
JP2007512368A (ja) 2007-05-17
PL1689724T3 (pl) 2012-05-31

Similar Documents

Publication Publication Date Title
CN1886384A (zh) 喹唑酮化合物作为抗癌药剂
CN1809563A (zh) 吡啶并[1,2－a]嘧啶－4－酮化合物用作抗癌药
CN1100046C (zh) 喹唑啉衍生物
CN1134438C (zh) 二环杂芳族化合物、其制备方法以及用途
CN1158266C (zh) 化合物
CN1798749A (zh) 作为抗癌剂的杂芳基－稠合的嘧啶基化合物
CN1910183A (zh) 四氢咔啉化合物作为抗癌药
CN1178932C (zh) 酰胺衍生物
CN1882345A (zh) 作为raf激酶抑制剂以治疗癌症的2,6－二取代的喹唑啉、喹喔啉、喹啉和异喹啉
CN1125817C (zh) 作为vegf抑制剂的喹唑啉衍生物
CN1138778C (zh) 用作细胞增殖抑制剂的二环嘧啶及二环3,4-二氢嘧啶化合物及用途
CN1305872C (zh) 喹唑啉类化合物的制备方法
CN1142919C (zh) 作为抗肿瘤剂的喹唑啉衍生物
CN100343238C (zh) 用作抗肿瘤药物的喹唑啉衍生物
CN1655779A (zh) 取代的吲哚及其作为Raf激酶抑制剂的应用
CN1094043A (zh) 喹唑啉衍生物
CN1678586A (zh) 取代的喹啉ccr5受体拮抗剂
CN1889951A (zh) 取代的苯并唑及其用作raf激酶抑制剂的应用
CN1071164A (zh) 含氮杂环化合物
CN1325390A (zh) 2－脲基噻唑衍生物及其制备方法和作为抗肿瘤剂的应用
CN1701073A (zh) 作为细胞周期蛋白依赖激酶抑制剂的吡唑并[1,5－a]嘧啶
CN1137037A (zh) 喹唑啉衍生物
CN1218456A (zh) 酪氨酸激酶的不可逆抑制剂
CN1237963A (zh) 抑制生长因子如vegf的作用的喹啉衍生物
CN1625555A (zh) 喹唑啉化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: NOVARTIS VACCINES & DIAGNOSTIC

Free format text: FORMER OWNER: CHIRON CORP.

Effective date: 20080530

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080530

Address after: Delaware

Applicant after: Novartis Vaccines & Diagnostic Inc.

Address before: American California

Applicant before: Chiron Corporation

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20061227